Israel’s ImmunoBrain Checkpoint aims to begin trials of its IBC-Ab002 treatment for Alzheimer’s disease. The antibody, developed by its Chief Scientist EMET Prize-winning Weizmann Institute Professor Michal Schwartz, boosts the immune system to induce brain repair processes.
Antibody for Alzheimer’s
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.